<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03390920</url>
  </required_header>
  <id_info>
    <org_study_id>#2017/05/6</org_study_id>
    <nct_id>NCT03390920</nct_id>
  </id_info>
  <brief_title>Evaluation of Outcomes With Umbilical Cord Allograft for Musculoskeletal Conditions Musculoskeletal Conditions</brief_title>
  <official_title>Evaluation of Regenerative Medicine Outcomes With Umbilical Allograft for Musculoskeletal Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>R3 Stem Cell</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>R3 Stem Cell</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to determine the efficacy of an Amniotic Fluid Tissue Product for&#xD;
      pain relief and functional improvements for all types of musculoskeletal conditions. The&#xD;
      study is prospective, with outcome measures being obtained at numerous time points after the&#xD;
      regenerative procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Medical providers are often faced with patients whose source of pain may be the result of an&#xD;
      inflammatory response caused by trauma or disease. By managing the patient's inflammation,&#xD;
      the clinician may see improved response to traditional pain management therapy and existing&#xD;
      protocols.&#xD;
&#xD;
      Also, degenerative arthritis of spinal and extremity joints may lead to significant low back,&#xD;
      knee, hip, shoulder pain etc, as the ratio of cartilage degradation to cartilage formation&#xD;
      increases with age. An amniotic tissue derived product may prove to be an ideal non-steroidal&#xD;
      and potentially regenerative therapy for use by the medical provider due to its unique&#xD;
      characteristics.&#xD;
&#xD;
      The orthopedic application of amniotic fluid dates back to at least the 1930's. The placental&#xD;
      membranes produce an array of immunosuppressive and anti-inflammatory molecules, which make&#xD;
      these tissues suitable for use as a wound covering [or as an anti-inflammatory] in a clinical&#xD;
      setting. In addition to structural properties, placental membrane and amniotic fluid (AF) is&#xD;
      a rich source of growth factors, including organic compounds and nutrients, hyaluronic acids,&#xD;
      amino acids, antioxidants and stem cells.&#xD;
&#xD;
      AF's anti-inflammatory actions may be mediated in part by its secretion of anti-inflammatory&#xD;
      cytokines including interleukin-10, inhibin, activin, and interleukin-1 receptor antagonist&#xD;
      as well as anti-inflammatory protease inhibitors such as âˆž-1 anti-trypsin inhibitor and&#xD;
      inter-a-trypsin inhibitor. AF may modulate acquired immunity by suppressing alloreactive&#xD;
      responses and down regulating production of Th1 and Th2 cytokines.&#xD;
&#xD;
      In addition to having known anti-inflammatory qualities, placental membrane cells, derived&#xD;
      from the layer of trophoblast cells covering the developing embryo, do not express MHC Class&#xD;
      II antigens, which are responsible for the rapid rejection of allografts in humans. Because&#xD;
      AF is immune privileged, it is an ideal allograft with no known graft-versus-host disease&#xD;
      (GVHD).&#xD;
&#xD;
      The amniotic fluid product may provide not only an anti-inflammatory response, but also&#xD;
      potentially yield regenerative effect or reduce further cartilage degeneration.&#xD;
&#xD;
      The objective of this study is to evaluate an amniotic fluid tissue product in the treatment&#xD;
      of pain due to all types of musculoskeletal conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">January 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Short Musculoskeletal Function Assessment Questionnaire (SMFA)</measure>
    <time_frame>Baseline and then Assess Changes Post Intervention at 4 weeks, 3 mths, 6 mths, 9 mths and one year</time_frame>
    <description>The Short Musculoskeletal Function Assessment Questionnaire (SMFA) is designed to measure the functional status of patients with a broad range of musculoskeletal injuries and disorders.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Work Status</measure>
    <time_frame>Baseline and then Assess Changes Post Intervention at 4 weeks, 3 mths, 6 mths, 9 mths and one year</time_frame>
    <description>Not Working, Part Time, Full Time, Retired</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS)</measure>
    <time_frame>Baseline and then Assess Changes Post Intervention at 4 weeks, 3 mths, 6 mths, 9 mths and one year</time_frame>
    <description>Assesses pain based on a scale from 0 to 100</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Tendinitis</condition>
  <condition>Sports Injury</condition>
  <condition>Degenerative Disc Disease</condition>
  <condition>Degenerative Arthritis</condition>
  <condition>Ligament Injury</condition>
  <condition>Neuropathy</condition>
  <condition>Pelvic Pain</condition>
  <arm_group>
    <arm_group_label>Umbilical Allograft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study is nonrandomized with one arm. Depending on the body area being treated, the amount of the product utilized will be either 1.0cc's or 2cc's.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Umbilical Allograft</intervention_name>
    <description>The umbilical allograft is regulated by the FDA and comes from a lab that is FDA registered.</description>
    <arm_group_label>Umbilical Allograft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 and over.&#xD;
&#xD;
          2. Ability to attend follow up visits or at least converse on phone or complete email&#xD;
             follow up forms.&#xD;
&#xD;
        4) Competent to understand the study protocol and provide voluntary informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active Infection&#xD;
&#xD;
          2. Pregnancy, Lactating&#xD;
&#xD;
          3. Clotting disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David Greene, PhD, MBA</last_name>
    <phone>844-438-7836</phone>
    <email>dgreene@r3stemcell.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Advanced Stem Cell Institute</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91316</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>David Greene, PhD</last_name>
      <phone>844-438-7836</phone>
      <email>info@r3stemcell.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Aagaard-Tillery KM, Silver R, Dalton J. Immunology of normal pregnancy. Semin Fetal Neonatal Med. 2006 Oct;11(5):279-95. Epub 2006 Jun 19. Review.</citation>
    <PMID>16784908</PMID>
  </results_reference>
  <results_reference>
    <citation>Shay E, Kheirkhah A, Liang L, Sheha H, Gregory DG, Tseng SC. Amniotic membrane transplantation as a new therapy for the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis. Surv Ophthalmol. 2009 Nov-Dec;54(6):686-96. doi: 10.1016/j.survophthal.2009.03.004. Epub 2009 Aug 21. Review.</citation>
    <PMID>19699503</PMID>
  </results_reference>
  <results_reference>
    <citation>Delo DM, De Coppi P, Bartsch G Jr, Atala A. Amniotic fluid and placental stem cells. Methods Enzymol. 2006;419:426-38. Review.</citation>
    <PMID>17141065</PMID>
  </results_reference>
  <results_reference>
    <citation>Soncini M, Vertua E, Gibelli L, Zorzi F, Denegri M, Albertini A, Wengler GS, Parolini O. Isolation and characterization of mesenchymal cells from human fetal membranes. J Tissue Eng Regen Med. 2007 Jul-Aug;1(4):296-305.</citation>
    <PMID>18038420</PMID>
  </results_reference>
  <results_reference>
    <citation>De Coppi P, Bartsch G Jr, Siddiqui MM, Xu T, Santos CC, Perin L, Mostoslavsky G, Serre AC, Snyder EY, Yoo JJ, Furth ME, Soker S, Atala A. Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol. 2007 Jan;25(1):100-6. Epub 2007 Jan 7.</citation>
    <PMID>17206138</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 19, 2017</study_first_submitted>
  <study_first_submitted_qc>December 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2018</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>regenerative medicine</keyword>
  <keyword>arthritis</keyword>
  <keyword>amniotic</keyword>
  <keyword>stem cell</keyword>
  <keyword>growth factor</keyword>
  <keyword>cartilage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
    <mesh_term>Tendinopathy</mesh_term>
    <mesh_term>Pelvic Pain</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Athletic Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data for all outcome measures will be made available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will be available within six months of study completion.</ipd_time_frame>
    <ipd_access_criteria>Solutions IRB is overseeing the study and will review data access requests.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 25, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT03390920/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

